CD19 and acute lymphoblastic leukemia: Further preclinical studies suggest that SAR3419 is highly effective in combination with standard induction chemotherapy (vincristine, dexamethasone, and l-asparaginase) for CD19 positive ALL, including chemoresistant subtypes such as Philadelphia positive ALL and infant MLL-ALL.